Most people taking Skyrizi for plaque psoriasis see major improvement within 16 weeks, with about 75% achieving 90% skin clearance by that point. The exact timeline depends on which condition you’re treating, since Skyrizi is now approved for four different diseases: plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Each has its own dosing schedule and its own pace of response.
Plaque Psoriasis: The Fastest Results
Skyrizi tends to work quickly for psoriasis compared to many other biologics. In clinical trials, more than 82% of patients had clear or almost clear skin by week 12. By week 16, roughly 75% had achieved a 90% reduction in their psoriasis severity, and between 36% and 51% were completely clear. Those numbers held up well against two other well-known biologics, outperforming both by a wide margin at the same time point.
The dosing schedule helps explain this speed. You get your first injection at week 0, a second at week 4, and then one every 12 weeks after that. Those two closely spaced starter doses build up drug levels in your body quickly, which is why many people notice visible improvement within the first month or two.
Results continue improving beyond week 16. By one year, about 81% of patients had 90% skin clearance, and roughly 56 to 60% were completely clear. Long-term data from an extension trial lasting nearly six years showed these gains held: at week 304, 86% of patients still had 90% clearance, and 54% maintained fully clear skin. Quality-of-life scores followed a similar pattern, with 76% reporting that psoriasis had no effect on their daily life at that same time point.
Psoriatic Arthritis: Gradual Joint Improvement
Joint symptoms take a bit longer to respond than skin symptoms. The dosing schedule is the same as for psoriasis (injections at weeks 0, 4, and every 12 weeks), but the primary results are measured later. In the largest trials, about 51 to 57% of patients hit a meaningful improvement in joint symptoms by week 24, compared to roughly 27 to 34% on placebo.
Earlier data from a phase 2 trial showed that about 60% of patients had meaningful joint improvement by week 16, so some people do respond faster. Response rates kept climbing through a year of treatment. By week 52, about 75% of patients had at least a 20% improvement in joint symptoms, and 44% had reached a 50% improvement. If you’re treating psoriatic arthritis, it’s reasonable to expect gradual gains over several months rather than a dramatic early shift.
Crohn’s Disease: A Different Dosing Approach
For Crohn’s disease, Skyrizi uses a more aggressive induction phase. Instead of self-injections, you receive three IV infusions of 600 mg at weeks 0, 4, and 8. Some patients notice improvement surprisingly early: clinical response and remission occurred as early as week 4 in a greater proportion of patients on Skyrizi versus placebo.
The primary checkpoint is week 12. At that point, 42 to 45% of patients were in clinical remission, compared to 20 to 25% on placebo. Endoscopic response, meaning visible healing of the intestinal lining, ranged from about 32 to 48% depending on how long patients had been living with Crohn’s before starting treatment. People diagnosed within the previous two years tended to respond better, with nearly 43% achieving clinical remission and 48% showing endoscopic healing.
After the induction phase, you switch to self-administered injections every 8 weeks for maintenance. By week 52, about 57 to 61% of patients who responded to induction were in remission. The takeaway for Crohn’s: expect to know whether the drug is working for you within the first 12 weeks, with continued improvement over the following months.
Ulcerative Colitis: Similar Induction, Slower Remission
Ulcerative colitis uses the highest induction dose of any Skyrizi indication: 1,200 mg by IV infusion at weeks 0, 4, and 8. Decreases in rectal bleeding and stool frequency were observed as early as 4 weeks. By week 12, 24% of patients achieved clinical remission versus 8% on placebo. That remission rate may sound modest, but ulcerative colitis is notoriously difficult to bring under control, and the gap over placebo is clinically significant.
The maintenance phase, using injections every 8 weeks, pushes those numbers higher. By week 52, 41 to 45% of patients who responded to induction were in remission, compared to 26% who switched to placebo. If you’re starting Skyrizi for ulcerative colitis, the first 12 weeks will give you a signal, but the full benefit unfolds over the course of a year.
Factors That Can Affect Your Timeline
Body weight is one variable. FDA review data showed that people weighing over 220 pounds (100 kg) had slightly lower drug concentrations in their blood, which translated to response rates about 3 to 7 percentage points lower at week 16 for psoriasis. The difference was small enough that no dose adjustment is recommended, but heavier patients may notice a slightly slower start.
A small number of patients develop antibodies against the drug, which can reduce how well it works. Those with higher antibody levels had roughly 30% lower drug concentrations and reduced efficacy. This isn’t something you can predict or prevent, but if you’re not seeing results on the expected timeline, it’s one reason your doctor might investigate.
Disease duration also plays a role, at least for Crohn’s. Patients with shorter disease duration, particularly under two years, consistently showed higher response rates across both clinical and endoscopic measures. This doesn’t mean Skyrizi won’t work for long-standing disease, but earlier treatment tends to produce faster, more complete results.
What a Realistic Timeline Looks Like
For psoriasis, many people see noticeable improvement within the first 4 to 8 weeks, with the clearest results by week 16. Continued improvement through the first year is common, and the response tends to be durable for years. For psoriatic arthritis, expect a more gradual improvement over 16 to 24 weeks, with gains continuing through the first year. For Crohn’s disease and ulcerative colitis, the induction IV infusions over the first 8 weeks are designed to get the drug working quickly, with initial results assessed at week 12 and maintenance benefits building through week 52.
If you’ve been on Skyrizi for 16 weeks and aren’t seeing meaningful improvement for your condition, that’s a reasonable point to reassess your treatment plan with your prescriber. Most people who respond to the drug show clear signs of benefit within that window.